Astrazeneca Pharma India Ltd.

NSE: ASTRAZEN BSE: 506820 SECTOR: Pharmaceuticals & Drugs  29k   234   39

3137.15
-111.90 (-3.44%)
NSE: Today, 03:59 PM

Price Summary

Today's High

₹ 3250

Today's Low

₹ 3126.35

52 Week High

₹ 4910

52 Week Low

₹ 2958.2

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

7842.88 Cr.

Enterprise Value

7490.53 Cr.

No. of Shares

2.5 Cr.

P/E

111.22

P/B

16.58

Face Value

₹ 2

Div. Yield

0.06 %

Book Value (TTM)

₹  189.16

CASH

352.35 Cr.

DEBT

0 Cr.

Promoter Holding

75 %

EPS (TTM)

₹  28.21

Sales Growth

-2.19%

ROE

22.83 %

ROCE

31.24%

Profit Growth

29.21 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Astrazeneca Pharma India Ltd.

Imdur Betaloc Seloken Ramace Plendil RHINOCORT Prostodin MERONEM XyloCaine SensorCaine Iressa Casodex CRESTOR

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-2.19%
3 Year12.53%
5 Year7.61%

Profit Growth

1 Year29.21%
3 Year53.28%
5 Year77.74%

ROE%

1 Year22.83%
3 Year21.56%
5 Year17.29%

ROCE %

1 Year31.24%
3 Year30.79%
5 Year25.95%

Debt/Equity

0

Price to Cash Flow

74.85

Interest Cover Ratio

117.596330275229

CFO/PAT (5 Yr. Avg.)

1.10585890493381

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2021 75 0
Jun 2021 75 0
Mar 2021 75 0
Dec 2020 75 0
Sep 2020 75 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 53.2750301592758% for the Past 3 years.
  • Company has been maintaining healthy ROE of 21.5643825289947% over the past 3 years.
  • Company has been maintaining healthy ROCE of 30.7940685694541% over the past 3 years.
  • Company is virtually debt free.
  • Company has a healthy Interest coverage ratio of 117.596330275229.
  • The company has an efficient Cash Conversion Cycle of -0.488196312999207 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.10585890493381.
  • The company has a high promoter holding of 75%.

 Limitations

  • The company has shown a poor revenue growth of 12.5255540027692% for the Past 3 years.
  • The company is trading at a high PE of 111.22.
  • The company is trading at a high EV/EBITDA of 64.4099.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021
Net Sales 209.48 200.25 210.26 175.4 197.71
Total Expenditure 173.72 169.51 169.85 159.77 179.79
Operating Profit 35.76 30.74 40.41 15.63 17.92
Other Income 4.71 2.93 2.55 2.9 2.84
Interest 0.28 0.26 0.28 0.27 0.25
Depreciation 4.62 5.11 5.84 4.76 4.28
Exceptional Items 0 0 0 0 0
Profit Before Tax 35.57 28.3 36.84 13.5 16.24
Tax 9.23 7.25 9.56 3.26 4.29
Profit After Tax 26.34 21.05 27.28 10.24 11.95
Adjusted EPS (Rs) 10.54 8.42 10.91 4.1 4.78

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Net Sales 543.71 571 728.29 831.81 813.56
Total Expenditure 506.77 524.71 656.99 711.11 678.09
Operating Profit 36.94 46.29 71.3 120.7 135.47
Other Income 14.39 12.25 16.29 12.99 12.84
Interest 0 0 0 1.14 1.09
Depreciation 15.83 14.74 14.92 18.58 20.13
Exceptional Items 0 0 0 0 0
Profit Before Tax 35.5 43.8 72.67 113.97 127.09
Tax 15.45 17.89 18.22 41.76 33.79
Net Profit 20.05 25.91 54.45 72.21 93.3
Adjusted EPS (Rs.) 8.02 10.36 21.78 28.88 37.32

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Equity and Liabilities
Share Capital 5 5 5 5 5
Total Reserves 217.87 241.93 295.8 359.44 451.17
Borrowings 0 0 0 0 0
Other N/C liabilities 88.68 109.73 22.75 44.13 44.6
Current liabilities 202.05 218.67 267.6 367.1 373.43
Total Liabilities 513.6 575.33 591.15 775.67 874.2
Assets
Net Block 86.84 75.46 74.83 71.53 80.96
Capital WIP 4.81 3.57 6.9 24.24 4.02
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 158.27 163.39 95.83 97.71 100.52
Other N/C Assets 0.42 0.27 0.25 0.01 0.01
Current Assets 263.26 332.64 413.34 582.18 688.69
Total Assets 513.6 575.33 591.15 775.67 874.2
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021
Profit from operations 35.5 43.8 72.67 113.97 127.09
Adjustment 14.61 3.39 7.62 9.75 14.2
Changes in Assets & Liabilities -0.24 -34.25 9.81 -2.66 -3.95
Tax Paid -11.77 -4.15 -35.12 -33.64 -32.56
Operating Cash Flow 38.1 8.79 54.98 87.42 104.78
Investing Cash Flow 0.25 -9.36 4.28 -170.8 173.03
Financing Cash Flow 0 0 0 -6.36 -8.97
Net Cash Flow 38.35 -0.57 59.26 -89.74 268.84

Corporate Actions

Investors Details

PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Promoters 75.00 75.00 75.00 75.00 75.00
astrazeneca pharma... 75.00 75.00 75.00 75.00 75.00
PARTICULARS Sep 2020% Dec 2020% Mar 2021% Jun 2021% Sep 2021%
Investors 25.00 25.00 25.00 25.00 25.00
tejas bhalchandra ... 2.56 2.56 2.63 2.67 2.67
tejas b trivedi - - - - -
shivani t trivedi - - 1.85 1.98 1.98
minaxi bhalchandra... 1.84 1.84 1.84 1.84 1.84
minaxi balachandra... - - - - -
shivani tejas triv... 1.81 1.81 - - -
icici prudential l... - - - - -
icici prudential l... 1.24 - - - -
reliance capital t... - - - - -
reliance capital t... - - - - -
iepf 0.46 0.46 0.46 0.46 0.45

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

  • PresentationQ3FY19 9 Jan 2020

Astrazeneca Pharma I Stock Price Analysis and Quick Research Report. Is Astrazeneca Pharma I an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Astrazeneca Pharma I and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 104.78 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Astrazeneca Pharma I has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Astrazeneca Pharma I , the EPS growth was 29.206481096801 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Astrazeneca Pharma I has OPM of 16.6515069570776 % which is a good sign for profitability.
     
  • ROE: Astrazeneca Pharma I have a healthy ROE of 22.8276427339344 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Astrazeneca Pharma I

X